Biaxin Xl

Cat-Scratch Disease, Sinusitis, Whooping Cough + 14 more

Treatment

21 FDA approvals

20 Active Studies for Biaxin Xl

What is Biaxin Xl

Clarithromycin

The Generic name of this drug

Treatment Summary

Clarithromycin is an antibiotic drug derived from erythromycin. It works by blocking the ability of bacteria to make proteins, which stops the bacteria from growing and multiplying. The effect of this drug can be either to stop the bacteria from growing (bacteriostatic) or to kill the bacteria (bactericidal), depending on the amount of the drug and type of bacteria.

Biaxin

is the brand name

image of different drug pills on a surface

Biaxin Xl Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Biaxin

Clarithromycin

1991

187

Approved as Treatment by the FDA

Clarithromycin, also known as Biaxin, is approved by the FDA for 21 uses which include Acute maxillary sinusitis and Bacterial Infections .

Acute maxillary sinusitis

Bacterial Infections

Otitis Media (OM)

Mycobacterial Infections

uncomplicated skin and subcutaneous tissue bacterial infections

prophylaxis of Mycobacterial infection

Acute Bacterial Exacerbation of Chronic Bronchitis (ABECB)

Duodenal ulcer caused by helicobacter pylori

Used to treat Duodenal ulcer caused by helicobacter pylori in combination with Amoxicillin

Tonsillitis streptococcal

Streptococcal Pharyngitis

Bronchitis, Chronic

Urinary Tract Infection (UTI)

HIV

Otitis

Duodenal Ulcer

Used to treat Duodenal ulcer caused by helicobacter pylori in combination with Amoxicillin

Mycobacterium Infections

Sinusitis

Community Acquired Pneumonia (CAP)

Bacterial Infections

Tuberculosis

Tonsillitis

Effectiveness

How Biaxin Xl Affects Patients

Clarithromycin is an antibiotic that can kill a variety of bacteria, including those that cause chest and sinus infections. It has been shown to be effective against certain types of strep, staph, Haemophilus, Moraxella, and Mycoplasma bacteria. It is usually a bacteriostatic (stops growth) but can be bactericidal (kills bacteria) depending on the concentration of the drug.

How Biaxin Xl works in the body

Clarithromycin is changed in the body to an active form and works with the original drug. It penetrates the walls of bacterial cells and attaches to their ribosomes, which are responsible for making proteins. It also affects proteins in the liver that help move drugs around the body.

When to interrupt dosage

The recommended portion of Biaxin Xl is contingent upon the diagnosed affliction, including Mycobacterium Infections, Lyme Disease and Bacterial Infections. The amount of dosage can be found in the table below, contingent upon the method of administration (e.g. Powder, for suspension or Capsule; Kit; Tablet).

Condition

Dosage

Administration

Mycobacterium Infections

, 500.0 mg, 250.0 mg, 250.0 mg/mL, 125.0 mg/mL, 1000.0 mg

, Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, film coated - Oral, Tablet, film coated, Kit, Tablet - Oral, Tablet, Tablet, coated, Tablet, coated - Oral, For suspension, For suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Tablet, extended release, Tablet, extended release - Oral, Capsule; Capsule, delayed release; Kit; Tablet, Capsule; Capsule, delayed release; Kit; Tablet - Oral, Kit - Oral

Bacterial Infections

, 500.0 mg, 250.0 mg, 250.0 mg/mL, 125.0 mg/mL, 1000.0 mg

, Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, film coated - Oral, Tablet, film coated, Kit, Tablet - Oral, Tablet, Tablet, coated, Tablet, coated - Oral, For suspension, For suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Tablet, extended release, Tablet, extended release - Oral, Capsule; Capsule, delayed release; Kit; Tablet, Capsule; Capsule, delayed release; Kit; Tablet - Oral, Kit - Oral

Tuberculosis

, 500.0 mg, 250.0 mg, 250.0 mg/mL, 125.0 mg/mL, 1000.0 mg

, Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, film coated - Oral, Tablet, film coated, Kit, Tablet - Oral, Tablet, Tablet, coated, Tablet, coated - Oral, For suspension, For suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Tablet, extended release, Tablet, extended release - Oral, Capsule; Capsule, delayed release; Kit; Tablet, Capsule; Capsule, delayed release; Kit; Tablet - Oral, Kit - Oral

Bacterial Endocarditis

, 500.0 mg, 250.0 mg, 250.0 mg/mL, 125.0 mg/mL, 1000.0 mg

, Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, film coated - Oral, Tablet, film coated, Kit, Tablet - Oral, Tablet, Tablet, coated, Tablet, coated - Oral, For suspension, For suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Tablet, extended release, Tablet, extended release - Oral, Capsule; Capsule, delayed release; Kit; Tablet, Capsule; Capsule, delayed release; Kit; Tablet - Oral, Kit - Oral

Duodenal Ulcer

, 500.0 mg, 250.0 mg, 250.0 mg/mL, 125.0 mg/mL, 1000.0 mg

, Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, film coated - Oral, Tablet, film coated, Kit, Tablet - Oral, Tablet, Tablet, coated, Tablet, coated - Oral, For suspension, For suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Tablet, extended release, Tablet, extended release - Oral, Capsule; Capsule, delayed release; Kit; Tablet, Capsule; Capsule, delayed release; Kit; Tablet - Oral, Kit - Oral

HIV

, 500.0 mg, 250.0 mg, 250.0 mg/mL, 125.0 mg/mL, 1000.0 mg

, Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, film coated - Oral, Tablet, film coated, Kit, Tablet - Oral, Tablet, Tablet, coated, Tablet, coated - Oral, For suspension, For suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Tablet, extended release, Tablet, extended release - Oral, Capsule; Capsule, delayed release; Kit; Tablet, Capsule; Capsule, delayed release; Kit; Tablet - Oral, Kit - Oral

Bronchitis, Chronic

, 500.0 mg, 250.0 mg, 250.0 mg/mL, 125.0 mg/mL, 1000.0 mg

, Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, film coated - Oral, Tablet, film coated, Kit, Tablet - Oral, Tablet, Tablet, coated, Tablet, coated - Oral, For suspension, For suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Tablet, extended release, Tablet, extended release - Oral, Capsule; Capsule, delayed release; Kit; Tablet, Capsule; Capsule, delayed release; Kit; Tablet - Oral, Kit - Oral

Bacterial Endocarditis

, 500.0 mg, 250.0 mg, 250.0 mg/mL, 125.0 mg/mL, 1000.0 mg

, Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, film coated - Oral, Tablet, film coated, Kit, Tablet - Oral, Tablet, Tablet, coated, Tablet, coated - Oral, For suspension, For suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Tablet, extended release, Tablet, extended release - Oral, Capsule; Capsule, delayed release; Kit; Tablet, Capsule; Capsule, delayed release; Kit; Tablet - Oral, Kit - Oral

Community Acquired Pneumonia (CAP)

, 500.0 mg, 250.0 mg, 250.0 mg/mL, 125.0 mg/mL, 1000.0 mg

, Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, film coated - Oral, Tablet, film coated, Kit, Tablet - Oral, Tablet, Tablet, coated, Tablet, coated - Oral, For suspension, For suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Tablet, extended release, Tablet, extended release - Oral, Capsule; Capsule, delayed release; Kit; Tablet, Capsule; Capsule, delayed release; Kit; Tablet - Oral, Kit - Oral

Streptococcal Pharyngitis

, 500.0 mg, 250.0 mg, 250.0 mg/mL, 125.0 mg/mL, 1000.0 mg

, Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, film coated - Oral, Tablet, film coated, Kit, Tablet - Oral, Tablet, Tablet, coated, Tablet, coated - Oral, For suspension, For suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Tablet, extended release, Tablet, extended release - Oral, Capsule; Capsule, delayed release; Kit; Tablet, Capsule; Capsule, delayed release; Kit; Tablet - Oral, Kit - Oral

Cat-Scratch Disease

, 500.0 mg, 250.0 mg, 250.0 mg/mL, 125.0 mg/mL, 1000.0 mg

, Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, film coated - Oral, Tablet, film coated, Kit, Tablet - Oral, Tablet, Tablet, coated, Tablet, coated - Oral, For suspension, For suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Tablet, extended release, Tablet, extended release - Oral, Capsule; Capsule, delayed release; Kit; Tablet, Capsule; Capsule, delayed release; Kit; Tablet - Oral, Kit - Oral

Sinusitis

, 500.0 mg, 250.0 mg, 250.0 mg/mL, 125.0 mg/mL, 1000.0 mg

, Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, film coated - Oral, Tablet, film coated, Kit, Tablet - Oral, Tablet, Tablet, coated, Tablet, coated - Oral, For suspension, For suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Tablet, extended release, Tablet, extended release - Oral, Capsule; Capsule, delayed release; Kit; Tablet, Capsule; Capsule, delayed release; Kit; Tablet - Oral, Kit - Oral

Whooping Cough

, 500.0 mg, 250.0 mg, 250.0 mg/mL, 125.0 mg/mL, 1000.0 mg

, Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, film coated - Oral, Tablet, film coated, Kit, Tablet - Oral, Tablet, Tablet, coated, Tablet, coated - Oral, For suspension, For suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Tablet, extended release, Tablet, extended release - Oral, Capsule; Capsule, delayed release; Kit; Tablet, Capsule; Capsule, delayed release; Kit; Tablet - Oral, Kit - Oral

Lyme Disease

, 500.0 mg, 250.0 mg, 250.0 mg/mL, 125.0 mg/mL, 1000.0 mg

, Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, film coated - Oral, Tablet, film coated, Kit, Tablet - Oral, Tablet, Tablet, coated, Tablet, coated - Oral, For suspension, For suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Tablet, extended release, Tablet, extended release - Oral, Capsule; Capsule, delayed release; Kit; Tablet, Capsule; Capsule, delayed release; Kit; Tablet - Oral, Kit - Oral

Urinary Tract Infection (UTI)

, 500.0 mg, 250.0 mg, 250.0 mg/mL, 125.0 mg/mL, 1000.0 mg

, Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, film coated - Oral, Tablet, film coated, Kit, Tablet - Oral, Tablet, Tablet, coated, Tablet, coated - Oral, For suspension, For suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Tablet, extended release, Tablet, extended release - Oral, Capsule; Capsule, delayed release; Kit; Tablet, Capsule; Capsule, delayed release; Kit; Tablet - Oral, Kit - Oral

Tonsillitis

, 500.0 mg, 250.0 mg, 250.0 mg/mL, 125.0 mg/mL, 1000.0 mg

, Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, film coated - Oral, Tablet, film coated, Kit, Tablet - Oral, Tablet, Tablet, coated, Tablet, coated - Oral, For suspension, For suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Tablet, extended release, Tablet, extended release - Oral, Capsule; Capsule, delayed release; Kit; Tablet, Capsule; Capsule, delayed release; Kit; Tablet - Oral, Kit - Oral

Otitis

, 500.0 mg, 250.0 mg, 250.0 mg/mL, 125.0 mg/mL, 1000.0 mg

, Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, film coated - Oral, Tablet, film coated, Kit, Tablet - Oral, Tablet, Tablet, coated, Tablet, coated - Oral, For suspension, For suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Tablet, extended release, Tablet, extended release - Oral, Capsule; Capsule, delayed release; Kit; Tablet, Capsule; Capsule, delayed release; Kit; Tablet - Oral, Kit - Oral

Warnings

Biaxin Xl Contraindications

Condition

Risk Level

Notes

Liver Dysfunction

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Jaundice, Obstructive

Do Not Combine

There are 20 known major drug interactions with Biaxin Xl.

Common Biaxin Xl Drug Interactions

Drug Name

Risk Level

Description

(R)-warfarin

Major

The metabolism of (R)-warfarin can be decreased when combined with Clarithromycin.

(S)-Warfarin

Major

The metabolism of (S)-Warfarin can be decreased when combined with Clarithromycin.

1,2-Benzodiazepine

Major

The metabolism of 1,2-Benzodiazepine can be decreased when combined with Clarithromycin.

3,5-diiodothyropropionic acid

Major

The metabolism of 3,5-diiodothyropropionic acid can be decreased when combined with Clarithromycin.

5-androstenedione

Major

The metabolism of 5-androstenedione can be decreased when combined with Clarithromycin.

Biaxin Xl Toxicity & Overdose Risk

Taking too much clarithromycin may cause diarrhea, nausea, bad taste, indigestion, and stomach pain. Some people may experience temporary hearing loss or discolored teeth, which can be fixed with a dental cleaning. Allergic reactions such as hives and skin rashes, as well as rare cases of anaphylaxis and Stevens-Johnson syndrome, have been reported. Liver damage and failure, which can be fatal in some cases, can also occur. Animal studies have linked clarithromycin to birth defects such as heart defects, cleft palate, and slowed growth. It is also known to cause an irregular

image of a doctor in a lab doing drug, clinical research

Biaxin Xl Novel Uses: Which Conditions Have a Clinical Trial Featuring Biaxin Xl?

Currently, 160 active clinical trials are being conducted to assess the efficacy of Biaxin XL in providing relief from Pertussis, HIV and Urinary Tract Infection (UTI).

Condition

Clinical Trials

Trial Phases

Mycobacterium Infections

0 Actively Recruiting

Whooping Cough

0 Actively Recruiting

HIV

155 Actively Recruiting

Phase 2, Phase 1, Phase 3, Not Applicable, Phase 4, Early Phase 1

Urinary Tract Infection (UTI)

6 Actively Recruiting

Phase 1, Phase 3, Phase 4, Phase 2

Streptococcal Pharyngitis

0 Actively Recruiting

Tonsillitis

0 Actively Recruiting

Community Acquired Pneumonia (CAP)

5 Actively Recruiting

Not Applicable, Phase 1, Phase 3

Otitis

0 Actively Recruiting

Cat-Scratch Disease

0 Actively Recruiting

Sinusitis

0 Actively Recruiting

Bronchitis, Chronic

0 Actively Recruiting

Bacterial Infections

0 Actively Recruiting

Bacterial Endocarditis

1 Actively Recruiting

Not Applicable

Duodenal Ulcer

0 Actively Recruiting

Bacterial Endocarditis

0 Actively Recruiting

Tuberculosis

0 Actively Recruiting

Lyme Disease

3 Actively Recruiting

Phase 1, Phase 2, Phase 3, Not Applicable

Biaxin Xl Reviews: What are patients saying about Biaxin Xl?

5

Patient Review

6/28/2011

Biaxin Xl for Acute Maxillary Sinus H. Influenzae Bacteria Infection

This cough syrup really helped me clear out my sinuses and feel better overall.

5

Patient Review

3/28/2010

Biaxin Xl for Acute Maxillary Sinus H. Influenzae Bacteria Infection

I am taking the generic form of Biaxin XL for a sinus infection. I have experienced some bad taste, but that is the only negative reaction. The medicine is clearing my sinus infection and I am quite pleased with it.

5

Patient Review

4/7/2009

Biaxin Xl for Severe Episode of Chronic Bronchitis due to Streptococcus Pneumoniae

I'm curious if this medication contains any gluten.

5

Patient Review

9/11/2014

Biaxin Xl for Pneumonia caused by Bacteria

I've found that Biaxin is really effective against pneumonia and sinus infections, even if it does cause a bit of a tinny taste in your mouth. White grape juice helps with that.

4.7

Patient Review

11/16/2010

Biaxin Xl for Pneumonia caused by Bacteria

Biaxin xl was much more effective than the other antibiotic I tried, and with minimal side effects.

4.3

Patient Review

4/4/2009

Biaxin Xl for Acute Maxillary Sinus M. Catarrhalis Bacteria Infection

The generic version I took was a yellow pill, which was similar to the non-generic. It worked well for me, with the only side effect being the bad taste in my mouth. This was most noticeable when I woke up, but it wasn't a problem at other times.

4.3

Patient Review

10/24/2009

Biaxin Xl for Pneumonia caused by Bacteria

I've only been taking this for four days, but my hearing has become very muffled. There's no pain, just some pressure in my ears. I don't feel any better yet, but hopefully the effects will kick in soon.

3

Patient Review

1/14/2010

Biaxin Xl for Bacterial Infection with Chronic Bronchitis

I fainted after taking this medication on an empty stomach.

2.7

Patient Review

2/15/2014

Biaxin Xl for Acute Bacterial Infection of the Sinuses

I'm not convinced this medication does much of anything for sinus, as I haven't noticed a difference. However, it does leave an incredibly unpleasant taste in your mouth that lasts for hours afterwards, and also causes excessive sweating. Additionally, it's made my hot flashes come back with a vengeance.

2.7

Patient Review

11/30/2012

Biaxin Xl for Pneumonia caused by Bacteria

I didn't have a great experience with this medication. I started feeling nauseous, lightheaded, and weak pretty quickly after starting my dosage. I had to increase how often I took the drug just to make it bearable.

2

Patient Review

2/27/2014

Biaxin Xl for Acute Bacterial Infection of the Sinuses

Not very effective for sinus infections!

1.3

Patient Review

5/21/2009

Biaxin Xl for Acute Maxillary Sinus H. Influenzae Bacteria Infection

I've only been taking this for four days and I'm already experiencing a range of negative side effects, from hot flashes to lightheadedness. I wouldn't recommend it.

1.3

Patient Review

3/9/2014

Biaxin Xl for Acute Maxillary Sinus H. Influenzae Bacteria Infection

The side effects of this treatment are extreme weight loss, diarrhea, vomiting, and dizziness.

1

Patient Review

12/18/2011

Biaxin Xl for Acute Maxillary Sinus M. Catarrhalis Bacteria Infection

I took 1000 mg of this once daily for ten days to treat a sinus infection. I barely noticed any difference; I still had pain and congestion. After finishing the medication, my symptoms got worse within a week. I'm now on Avelox which is working much better. The only downside is that it gives me occasional chest pain at night.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about biaxin xl

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is clarithromycin XL 500mg used for?

"Clarithromycin is an antibiotic used to treat various bacterial infections. These include pneumonia, bronchitis, and infections of the ears, sinuses, skin, and throat."

Answered by AI

What infections does Biaxin treat?

"Biaxin is an antibiotic that is used to treat various bacterial infections. These infections include skin and middle ear infections, tonsillitis, throat infections, laryngitis, pneumonia, and tuberculosis."

Answered by AI

What is Biaxin XL used for?

"Biaxin XL (clarithromycin) is a macrolide antibiotic that fights bacteria in your body. Biaxin XL is used to treat many different types of bacterial infections affecting the skin and respiratory system. Biaxin XL is also used together with other medicines to treat stomach ulcers caused by Helicobacter pylori. May 17, 2022"

Answered by AI

Is Biaxin the same as amoxicillin?

"The medication Amoxil is used to treat bacterial infections while Biaxin is used as a first-choice medicine to treat common respiratory infections. Both medications may cause side-effects, but they are typically mild."

Answered by AI

Clinical Trials for Biaxin Xl

Image of New Jersey Community Research Initiative in Newark, United States.

AI-DBT for Suicide Prevention in HIV/AIDS

18+
All Sexes
Newark, NJ

One in four older persons living with HIV/AIDS (PLWHA) report at least one suicide attempt in their lifetime, and the risk for death by suicide is 100 times higher in PLWHA than in the general population. Currently, there are no behavioral interventions that specifically address suicide prevention for older PLWHA, despite their unique biopsychosocial and structural risk factors. Through this work, investigators will adapt Dialectical Behavior Therapy, an evidence-based intervention for suicide prevention, for patients with PLWHA to be delivered by an AI-powered conversational Agent developed by our industry partner, Empower Health. Investigators will then pilot test the feasibility, usability, acceptability and preliminary efficacy to improve self-efficacy to manage negative emotions in n=50 older adults living with HIV/AIDS.

Recruiting
Has No Placebo

New Jersey Community Research Initiative (+1 Sites)

Elissa Kozlov, PhD

Image of George Washington University Emergency Department in Washington D.C., United States.

Decision Support Tool for HIV Prevention

18+
All Sexes
Washington D.C., United States

This project will explore the development of a personalized decision support tool to assist with pre-exposure prophylaxis (PrEP) initiation and persistence among patients identified in the emergency department (ED) and urgent care settings as PrEP eligible. First, the investigators will use a sequence of validated implementation science methodologies to develop and validate a decision support tool designed to optimize PrEP persistence by strengthening self-efficacy by addressing the multifaceted medical and social needs of the individual patient. The investigators will then test the preliminary effectiveness of this tool through a pilot stepped wedge implementation trial in two EDs and an urgent care in Baltimore, MD and Washington, DC among 120 PrEP eligible patients to determine PrEP initiation, linkage to care, persistence, and adherence rates.

Phase 1
Waitlist Available

George Washington University Emergency Department (+1 Sites)

Image of The University of Alabama at Birmingham in Birmingham, United States.

Behavioral vs Mindfulness Treatments for Insomnia in HIV

50 - 99
All Sexes
Birmingham, AL

The goal of this clinical trial is to examine the effects of a telephone-delivered Brief Behavioral Treatment Insomnia (BBTI) versus a Brief Mindfulness Treatment (BMT) on cognitive and sleep outcomes in older adults with HIV. The main questions it aims to answer are: What are the effects of BBTI vs BMT on self-reported and observed sleep outcomes in older adults with HIV and insomnia up to 1-year post-intervention? What are the effects of BBTI vs BMT on self-reported and observed cognitive comes in older adults with HIV and insomnia up to 1-year post-intervention? What is the association between Alzheimer's Disease biomarkers and sleep and cognitive outcomes in older adults with HIV receiving BBTI vs BMT? Participants will: * Complete 4 weeks of telephone-delivered BBTI or BMT * Attend baseline, post-intervention, and 1-year post in-person visits for sleep and cognitive assessments * Have blood collected at all three time points

Waitlist Available
Has No Placebo

The University of Alabama at Birmingham (+1 Sites)

Dr. Shameka L Cody, PhD, AGNP-C, PMHNP-BC, FAAN

Image of University of Alabama at Birmingham in Birmingham, United States.

Olfactory Training for HIV

18+
All Sexes
Birmingham, AL

The goal of this study is to examine two types of olfactory interventions (olfactory training vs overnight odor diffuser) in adults with HIV. The two research questions are: 1. Determine if participants find the intervention acceptable and assess feasibility of the study. 2. Determine if the intervention improves olfactory function and cognitive function. Participants will come to our office and be administered the baseline battery of questions including olfactory and cognitive performance tests. Then they will be randomized and sent home with one of the two interventions (below) in which they will engage in it for 8 weeks, after which they come back to our office for the posttest battery of questions including olfactory and cognitive performance test. 1. Olfactory Training at Home -- 4 scents in which they will smell twice a day for 8 weeks. 2. Overnight Diffuser Group -- a single scent diffuser that participants will turn on while they sleep and use for 8 weeks.

Phase < 1
Waitlist Available

University of Alabama at Birmingham

Have you considered Biaxin Xl clinical trials?

We made a collection of clinical trials featuring Biaxin Xl, we think they might fit your search criteria.
Go to Trials
Image of University of North Carolina in Chapel Hill, United States.

MGD020 + MGD014 for HIV

18 - 65
All Sexes
Chapel Hill, NC

This research study aims to find out how safe and well tolerated the experimental study drugs are when given to persons with HIV (PWH) taking antiretroviral therapy (ART). The study treatments are MGD014 and MGD020, which are two antibodies developed specifically for HIV, and Vorinostat, an oral medication to help expose HIV in cells to the antibodies. The study will measure the impact of study treatment on non-active HIV in cells, and how long MGD014 and MGD020 stay in the body after they are given. In this study, participants will be randomly assigned to one of three groups. All participants receive MGD014 and MGD020, given sequentially as infusions through an IV for 4 doses. Participants in one group (group A) receive only MGD014 and MGD020. Participants in another group (group B) will stop taking their ART therapy for up to 8 weeks (a temporary treatment interruption (TTI)) while receiving MGD014 and MGD020. Participants in the third group (group C) receive Vorinostat in addition to MGD014 and MGD020. Total time of participation is about 8 months and involves 13 or 18 visits, depending on group assignment.

Phase 1
Recruiting

University of North Carolina

Cynthia L. Gay, MD

Image of Center on Substance Use and Health in San Francisco, United States.

CHAMPION Intervention for Pre-exposure Prophylaxis Adherence

18 - 40
Male
San Francisco, CA

The goal of this randomized controlled trial is to pilot test new mobile health (mHealth) interventions to improve PrEP adherence among HIV-negative men who have sex with men (MSM) with mild to moderate methamphetamine use disorder (MUD). The CHAMPION intervention combines two mHealth tools-PrEPAPP and CBT4CBT-to address both HIV prevention and MUD treatment needs in this population. The study's specific aims are: * To evaluate the feasibility and acceptability of the CHAMPION intervention based on treatment retention and engagement rates. * To examine the preliminary efficacy the CHAMPION intervention to improve PrEP adherence, as measured by dried blood spot (DBS) tests compared to the waitlist control group.

Waitlist Available
Has No Placebo

Center on Substance Use and Health

Glenn-Milo Santos, PhD, MPH

Have you considered Biaxin Xl clinical trials?

We made a collection of clinical trials featuring Biaxin Xl, we think they might fit your search criteria.
Go to Trials

Have you considered Biaxin Xl clinical trials?

We made a collection of clinical trials featuring Biaxin Xl, we think they might fit your search criteria.
Go to Trials